These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 24582532)

  • 1. Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL).
    Arsenault BJ; Boekholdt SM; Mora S; DeMicco DA; Bao W; Tardif JC; Amarenco P; Pedersen T; Barter P; Waters DD
    Am J Cardiol; 2014 Apr; 113(8):1378-82. PubMed ID: 24582532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of smoking on cardiovascular events in patients with coronary disease receiving contemporary medical therapy (from the Treating to New Targets [TNT] and the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] trials).
    Frey P; Waters DD; DeMicco DA; Breazna A; Samuels L; Pipe A; Wun CC; Benowitz NL
    Am J Cardiol; 2011 Jan; 107(2):145-50. PubMed ID: 21129718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes.
    Waters DD; Ho JE; Boekholdt SM; DeMicco DA; Kastelein JJ; Messig M; Breazna A; Pedersen TR
    J Am Coll Cardiol; 2013 Jan; 61(2):148-52. PubMed ID: 23219296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease.
    Stoekenbroek RM; Boekholdt SM; Fayyad R; Laskey R; Tikkanen MJ; Pedersen TR; Hovingh GK;
    Heart; 2015 Mar; 101(5):356-62. PubMed ID: 25595417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
    Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
    Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
    LaRosa JC; Grundy SM; Kastelein JJ; Kostis JB; Greten H;
    Am J Cardiol; 2007 Sep; 100(5):747-52. PubMed ID: 17719314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
    LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJ; Shepherd J; Wenger NK;
    N Engl J Med; 2005 Apr; 352(14):1425-35. PubMed ID: 15755765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statin and the risk of renal-related serious adverse events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and other placebo-controlled trials.
    Bangalore S; Fayyad R; Hovingh GK; Laskey R; Vogt L; DeMicco DA; Waters DD;
    Am J Cardiol; 2014 Jun; 113(12):2018-20. PubMed ID: 24793673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
    Heintjes EM; Penning-van Beest FJ; Plat AW; Meerding WJ; Webb K; Sturkenboom MC; Herings RM
    Pharmacotherapy; 2012 Jul; 32(7):631-41. PubMed ID: 22760692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid lowering in patients with treatment-resistant hypertension: an analysis from the Treating to New Targets (TNT) trial.
    Bangalore S; Fayyad R; Laskey R; DeMicco D; Deedwania P; Kostis JB; Messerli FH;
    Eur Heart J; 2014 Jul; 35(27):1801-8. PubMed ID: 23990605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] Study).
    Johnson C; Waters DD; DeMicco DA; Breazna A; Bittner V; Greten H; Grundy SM; LaRosa JC
    Am J Cardiol; 2008 Nov; 102(10):1312-7. PubMed ID: 18993147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial).
    Pedersen TR; Cater NB; Faergeman O; Kastelein JJ; Olsson AG; Tikkanen MJ; Holme I; Larsen ML; Lindahl C; Szarek M
    Am J Cardiol; 2010 Aug; 106(3):354-9. PubMed ID: 20643245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study.
    Waters DD; LaRosa JC; Barter P; Fruchart JC; Gotto AM; Carter R; Breazna A; Kastelein JJ; Grundy SM
    J Am Coll Cardiol; 2006 Nov; 48(9):1793-9. PubMed ID: 17084252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of female sex on lipid lowering, clinical outcomes, and adverse effects in atorvastatin trials.
    Hsue PY; Bittner VA; Betteridge J; Fayyad R; Laskey R; Wenger NK; Waters DD
    Am J Cardiol; 2015 Feb; 115(4):447-53. PubMed ID: 25637322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studies.
    Arsenault BJ; Boekholdt SM; Hovingh GK; Hyde CL; DeMicco DA; Chatterjee A; Barter P; Deedwania P; Waters DD; LaRosa JC; Pedersen TR; Kastelein JJ;
    Circ Cardiovasc Genet; 2012 Feb; 5(1):51-7. PubMed ID: 22135385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study).
    Foody JM; Brown WV; Zieve F; Adewale AJ; Flaim D; Lowe RS; Jones-Burton C; Tershakovec AM
    Am J Cardiol; 2010 Nov; 106(9):1255-63. PubMed ID: 21029821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial.
    Tikkanen MJ; Szarek M; Fayyad R; Holme I; Cater NB; Faergeman O; Kastelein JJ; Olsson AG; Larsen ML; Lindahl C; Pedersen TR;
    J Am Coll Cardiol; 2009 Dec; 54(25):2353-7. PubMed ID: 20082922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study).
    Tikkanen MJ; Holme I; Cater NB; Szarek M; Faergeman O; Kastelein JJ; Olsson AG; Larsen ML; Lindahl C; Pedersen TR;
    Am J Cardiol; 2009 Mar; 103(5):577-82. PubMed ID: 19231315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
    Sever PS; Poulter NR; Dahlof B; Wedel H;
    J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose statin therapy for secondary prevention of stroke: stroke prevention by aggressive reduction in cholesterol levels study review.
    Schwertz DW; Badellino KO
    J Cardiovasc Nurs; 2008; 23(1):8-13. PubMed ID: 18158500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.